IDE

Expensive-Past-69420

build a harness not IDE like a clawdbot or something

InTheMorning_Nightss

You do realize that Claude Code, Copilot, and Codex all have tens of thousands of users on both Enterprise and personal plans as well, right? “Enterprise scale repos” doesn’t even mean anything. Companies vary greatly in their code bases: monorepos, microservices, and everything in between. The majority of these ultimately leverage Git which is the more impactful technology when it comes to how nicely things play with repos. How you interact with the code between IDE solutions, CLI, etc. aren’t the differentiator in “Enterprise scale repos” as you call them (which nobody else does) besides language in some cases. My comment isn’t snarky: it’s pointing out how you are a single voice trying to discount the voice of another single voice, and it’s clear you lack the actual nuance here. Pointing to just Nvidia is meaningless. If you don’t think they using other AI solutions in the SDLC, you have a very narrow view.

imunfair

> why is a satellite company buying an IDE? SpaceX includes grok and xai, which are more related to cursor than the launch portion.

mehmet_okur

Cursor needs: massive compute they can't afford,ore capital injected Spacex needs: more very smart to engineers, desktop integration both win/Linux terminal (CLI), native win/Linux (GUI), and IDE. Grok currently has zero penetration into desktops outside of support for using their models in tools like VS Code. Spacex can fill those compute and capital needs in exchange for more super nerds and cursors established desktop platform IP (even if consensus is that Cursor had fallen off). To look at this and think "Elon out of touch, nobody uses cursor anymore, hurr durr" is goofy. spaceX is well aware that cursor product fell off the map compared to codex and Claude in 2026. Believe it or not, buying assets and companies when the market thinks they are dogshit is the most fundamental way to make money next to prostitution It may fail and end up being a terrible decision, who knows, that's not the point. They believe they are getting a cheap price based on how they value Cursor as a company. For example: Claude dominates market currently with a 90+% chance to be best objective AI on prediction markets for April 2026. This would be a bad time to buy anthropic unless you are the kind of guy to go all in on BTC at 120k ATH. That's what a guy in a clown suit told me while I was looking dinner in a dumpster tonight. Verbatim. Cool guy, a bit verbose though.

AskAboutMySecret

bro is spacex a SPAC? why is a satellite company buying an IDE? for 60 billion no less...

random_account6721

I only briefly used cursor, but I would think heavy IDE integration is on its way out. I just use this codex app to chat with a couple agent sessions and then VSCode to review the files changed. A couple years ago it was all about integrating AI into the developer writing code. Code completion and stuff like that, but now you don't really need to write much code. You're mostly just orchestrating agents and reviewing code. Cursor seems to be built on the developer coding layer when everything is moving to the agent orchestration layer. I don't see the value of this product except for the customer base they've built.

TheWetCouch

They dont use their own model, it just routes access to the big ones in an IDE context. Its literally just VSCode with an agent window that you can pick the models for, and they’ll do the charging for you as a middle man

Greedyanda

Its not one massive issue that makes it unusable, its just many small points of friction that highlight the difference between a project mostly designed by engineers and and a project that employs countless UX and design experts. I dont have it currently on any of my machines so I cant tell you in detail but even though I actually prefered Debian over other distros, it always left me a bit tired and aesthetically displeased when I had to do something besides opening the browser or working in my IDE. You can definitely improve and customize the experience but this will require quite a bit of additional time and knowledge and every couple of months something will break because the changes you made are no longer or not yet supported by the newest Linux version.

the_chosen_one2

Actual copium and 0 reading comprehension reply, I literally say it's much better than it was. It still doesn't provide that much value to a base good software engineer. Acting like its anything more than StackOverflow integrated into your IDE is cope or admitting you were a shit dev to begin with. I have no issue admitting it is better now; it undeniably is. You can actually use it as a coding assistant now. I'm saying it's not doing 95% of the shit AI bros were claiming it'd be doing by now.

Every-Promotion9883

Essentially a lot of the palantir saas items are going to become obsolete by AI. The only growth is b2b moving slower then b2c currently once b2b catches up the same result will happen and development might turn to IDE more

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting ‏FDA PHASE 3 completion in Q1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system PMDA approval in Japan ⁠55+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…) ‏Patents, IP and more…

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting ‏FDA PHASE 3 completion in Q1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system PMDA approval in Japan ⁠55+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…) ‏Patents, IP and more…

dr3amstate

Cursor is an IDE. You can use Codex, Claude Code and similar tools as an extension through Cursor or many other IDEs. So you can go ahead with Cursor and try whatever fit your needs

oddlogic

This company might take 5 years to implode, but it will. True agentic AI doesn’t need a .Net wrapper and a clumsy IDE paired with (admittedly very good) orchestration to be effective, and will be a fraction of the yearly cost, before we even begin to talk about all of the maintenance, BAs running queues, etc. A business can replace a $1M yearly UiPath licensing scenario with a developer (which you’re going to need anyway, if only for maintenance), and $20k? in tokens. If that much.

The_Meme_Economy

That’s a low key indictment of C++ tooling lol. The IDE really should be able to do a refactor but in reality most of them fall down at some point. I think you’d do fine without the LLM, your job would just be more tedious.

Tight_One_1400

Its not AI slip anymore - especially in the software world. AI is getting scary good. For now companies (at least my 1k dev+ company is) are just paying for AI assisted IDE's for their developers. The problem is, 5 pointer tickets take 5 mins, then another 1-2 hours to review, fix security issues and test. Meaning a good dev can do 2x 5pointer tickets in a day. Normally a 5-point ticket is one that takes 1-2 weeks.

ganari423

I agree with you on this statement.. I started out doing the copy paste into a chat window and got the most god awful solutions… I had to prompt specifically than correct the code.. with IDE chats.. it interprets the code base way better and returns damn good code. I still have to check it and test features properly.. but I went from few hundred lines of code a day to thousands 😭

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting ‏FDA PHASE 3 completion in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠55+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…) ‏Patents, IP and more…

Seref15

90%+ software engineering work is stuff like "Ticket #1003918 - Investigate slowness in the billing report handler". You're very rarely building brand new things. The way my AI workflow using Claude models in GH Copilot IDE extension would be something like highlighting a function I suspect is the culprit, entering into the flyout chat panel in my IDE: > I think this function causes slowness during large report generation. Resource utilization (cpu seconds, memory, heap, threads) during the slowness is all normal. Do you see where the bottleneck might be? Then it think for 2 minutes and comes back with something like > This function calls another function XYZ in the data object class that has a misconfigured thread pool, because of setting ABC, during scondition DEF it processes query GHI serially instead of in parallel And then you fix the thing thats wrong. Another thing we use it for a lot is, we have some codebase with absolutely no documentation but we need to understand how it works; > Starting at main.cs crawl every function call and add a node to a mermaid chart for each function and call; annotate each node with the function's purpose A lot of our busy work is done this way now. Even using my IDE copilot chat to automatically handle the opening/transitioning/closing of ticket items as I commit work to git. MCP servers let you do a lot with the chat models from your IDE now so its kind of a nice bonus feature that it eliminates a lot of context switching.

hydraByte

Are you implying I wrote my last comment with AI? Because I didn’t, I write almost all my Reddit comments by hand. What makes Gemini 3.1 stand out to you so far? I just started using it an hour ago and haven’t noticed any major differences yet (but it’s still pretty early). The jump from 2.5 to 3.0 was crazy, but I’m not convinced they can keep up that level of progress consistently going forward. I am currently using Google Antigravity as an agentic IDE for coding, generally switching between Gemini Pro and Claude models. I use it as a secondary tool because I prefer Jetbrains IDEs for precision coding and like I said I don’t like having it write code for me.  Aside from producing buggy code in complex use-cases, code generated via LLMs also weakens or eliminates a company’s copyright claim over the code, meaning if someone copies that code you might not have an effective legal mechanism means to stop them. It’s another barrier that complicates their usefulness — software companies have to start making the decision: “does this allow us to produce output that is better and faster enough that we are willing to offset the strength of our legal protections”?

derprondo

Going to be able to fund my retirement now with all my old sata hard drives, DDR2, and my collection of IDE cables.

btoned

This is NOT the case. These two platforms attract the LOWEST tier of talent. Have you ever seen the output? It's like using a coding IDE to spit out some boiler plate code, and I literally mean the boilerplate, and passing that off as your finished product and charging like $15 for it. These platforms got reach off of VC money that's it. Any respectable pro in their respective field would never recommend looking for talent on these platforms.

zed_roaster

I'm not so sure about that. I know many people, myself included, who have really appreciate using AI. It is super convenient and is awesome depending on the use case. The biggest thing as a non-technical person I was wow'd by was the coding IDE - being able to program your own tools in natural language was insane. Also, for work, it helps a ton when you need to solve a problem or use it to speed things up. So yeah, it is awesome and convenient honestly.

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠**55+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…) ‏Patents, IP and more…

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…) ‏Patents, IP and more…

Zardotab

>That said, let's be honest, most projects out there aren't super complex or novel. Most developers write and maintain CRUD apps, and that's the exact thing the models are getting pretty good at. That's true, but largely because the CRUD industry hitched its wagon to the defective DOM. Apps that used to take 2 weeks to build in PowerBuilder, Paradox, Delphi, etc. now take like 4 months. If the pendulum swings back to CRUD-oriented-IDE's instead of general IDE's with bajillion layers, then we wouldn't need auto-bloaters like scaffolders and AI nearly as much. Simply factor long-known CRUD idioms into standard modifiable attributes. Nobody seems interested in CRUD parsimony, just buzzword collection. But you are right that if we stick with the current Bloat Industrial Complex and the evil DOM, then AI is quite useful.

Natural-Revenue-6639

How is Cursor in anyway a competition? It's a coding IDE not design creation and management software. Design is so much more than stitching together a UI.

Salt_Inspector_641

I’ve been messing around on antigravity IDE and the agents are surprisingly good. You don’t think at the start of a project, you just prompt, go thru the details with the agent and then it just builds your first iteration. Saves me a lot of time in the planning stage

BoogieMan876

You haven't used copilot in vs code it seems , many big companies prefer that just bcuz you can access latest state of the art models right then in there in your IDE. Copilot is bigger and better structured than you think although I agree with everything else you said. Which is why I go with like VOO or VTI all of them I think will capture a specific marker with Google being at the forefront. Chatgpt will probably get acquired by msft

Jojje22

Someone gets it, and I agree 100% as I haven't gotten any good explanations either. And also, these are "just" the pure technical aspects of it. I don't see how AI solves the most complex aspect of all - allignment and requirements. This is what's been costly with sending stuff to contractors down south and AI won't manage it any better - what are we actually supposed to develop? What is our context? What are the dependencies? There are boatloads of external integrations, and stakeholders of all kinds with no knowledge of each other, how do we know what to interconnect? And I don't see how AI can *ever* solve this because this, and scaling an architecture, and organizing globally etc. isn't readily available information plus it's super contextual. *This* is what's costly to sort out and extremely constly when you get it wrong, the cost hasn't been about getting the for-loop down in the IDE for a very long time.

SheriffBartholomew

What are you talking about? Claude Code and Cursor are programming editors used by coders. Figma is a design tool used by designers. Designers make their designs in Figma, deliver them to developers, and the developers code them in their chosen IDE. The are completely different tools, for completely different professions. Although Figma is supposedly now capable of integrating with Cursor to output a design as functional code. I haven't seen that part of it work yet, but it wouldn't surprise me if it works well.

HotMessMan

Wow what kind of nonsense are you projecting here? What about my comment even hints at insecurity? It’s a tool, I used it, saved a ton of time on boring tedious parts of code, it’s incredible. It’s that simple. Your comment is akin to someone not using an IDE because it would make your skills less sharp and the IDE would do the thinking for you! Intellisense? Compile error detection ? Why I would never!

Worf_Of_Wall_St

Most of the time when I'm typing at work there is some AI constantly running queries to make suggestions for what I should type next. It's right maybe 1% of the time, so if I read every suggestion it's a time loss especially since I get derailed/distracted easily. I've learned which situations it might be useful in and try to ignore it the rest of the time, but it seems very wasteful to constantly be running queries with 2-3s inferencing times while I work. For things I specifically decide to ask an AI for because I think maybe it will work, I probably have a 1 in 10 success rate. A few times it has saved me a few hours of work because I only had to review what it did, but in those 9 out of 10 times there are a lot of hallucinations like you describe that send me looking for things which do not exist. The dead ends don't take a huge amount of time but they are annoying. I would guess that if AI was priced at what it actually costs to run plus amortized model training costs, the latter case where I ask it something specific would be worth paying for, but the thousands of prompts that are run all day while I type in an IDE or document would surely be a waste of money.

Gandalior

But then it's Windows 10 with a different IDE

Pristine_Hurry_4693

They have 5 (!) FDA IDE’s going on, that’s 5 clinical trials in different stages. The most advanced is already in Phase 3 and **started submitting the data to the FDA for approval**, the other trials includes the most high unmet needs cancers like GBM (successfully treated the first patient), Pancreas (Successfully treated the first patient as well but should be finishing all 30 this quarter) and more. On top of the in Japan they already finished all the trials and submitted everything and passed the final committee so just awaiting the approval announcement by the PMDA.

Spoonyyy

Totally get this. I'm a security engineer and I've been leveraging an AI-assisted IDE and it's definitely accelerated my development time. I've had to do some back and forth, but overall not as much as me having to work with an engineering team that has me do the same type of requirement, design, etc,.

SweatyMammal

There’s so many variables to the effectiveness of using AI for coding at the moment. Variables like: Which model are you using? What prompts are you using? Is it an existing codebase? Which IDE are you using? Are you using the ‘plan’ modes at one step and the ‘agent’ modes for the implementation? To get good results is definitely learning curve, and devs are hesitant to try using tools that can replace their jobs. It doesn’t help that everything gets lumped into a general ‘AI‘ bucket, which isn’t very useful when models can vary wildly in performance. I’m not surprised we’re not seeing huge upswings yet because it seems we’re still in that learning and experimentation phase as devs start to integrate it into their workflows. For new tools I wouldn’t think twice about using AI to create those. I’ve had good amounts of success with getting whole new tools set up in a couple hours or so.

soldier_18

Google has an entire ecosystem and they have been really smart on how they are integrating Gemini in an impressive velocity and google also owns around 14% of **Anthropic** (Claude) so thats interesting because Claude still remains in general as the best AI for coding, so its like the best of both worlds and with the new Antigravity IDE, google is killing it. Here is where you can see how Microsoft is getting so far behind, because they also have a massige ecosystem with OneDrive, Excel, PPT, Word, windows and Copilot is not even close to Gemini, Claude or Chatgpt. Anyways, I see Google achieving the dominance because of their capability to offer other stuff along with Gemini, they are being smart on attracting new clients or having other to upgrade their current plan, for example they give you 2TB storage with your PRO subscription (20$), again Microsoft can offer something similar but they are like sleeping in the water. And remember, Google was like 2 years behind all of them, really impresive.

foo-bar-nlogn-100

But it's just making AI slop. Like, how has it made anyone money other than NVDA. Every company I hear is losing money. I hear Cursor IDE is losing money now because of people migrating to Antigravity and Gemini. I am a bot.

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting Including ‏FDA PHASE 3 completion for one indication in H1 2026 ‏And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy… and of course Japan where they are expected approval) ‏Patents, IP and more…

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting Including ‏FDA PHASE 3 completion for one indication in H1 2026 ‏And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy… and of course Japan where they are expected approval) ‏Patents, IP and more…

Pristine_Hurry_4693

Keytruda is the #1 selling drug worldwide, all that despite only 19% of patients responding and only 5% showing complete response. Although a small sample size, but a combination therapy trial using Keytruda with a DRTS treatment (which has shown the ability to activate the immune system) has shown effectively 100% patient response and 50% complete response. If this holds up it’s an industry changer in and of itself, so the this is what they are potentially looking into with a larger trial and an FDA IDE to do so

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting Including ‏FDA PHASE 3 completion for one indication in H1 2026 ‏And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

CryptoThroway8205

I don't think many people are using self hosted deepseek as their model in their IDE to write code. In order to catch up you still need to train and even if the cost of chips crashes the cost of electricity and water won't. The difference between 80% accuracy and 85% is massive because of perception and companies are likely going to be the ones paying for the 85%. I think we're going to see free models better than self hosted deepseek disappear since they won't be able to keep running at cost to gain market share.

Pristine_Hurry_4693

Agree to disagree. First of all, sadly, there are enough cancer cases for many companies to be successful (please god let’s get to the day that a company could have a cancer treatment but the competition for good treatments outweighs the need for them) Secondly, DRTS is in phase 3 of the FDA with five IDE’s going on, expecting PMDA approval any day now, have all the cash on hand etc etc, the risk is almost nonexistent while the reward could be anywhere between 10-100+ per share (with 10 coming in the next quarter and 100+ coming after)

Pristine_Hurry_4693

Happy to hear you read about it, that’s the real point of the post (always DYOR, although I do believe it’s a good buy) Of course it’s NFA, and I understand the hesitancy and would never tell anyone if or when to buy, I would just note that it was sitting around 4$ and has then risen off of real good news (specifically the GBM, but that’s after the Pancreas as well, getting FDA approval for the manufacturing facility, getting an IDE for Prostate and more and more), so even if the price corrects a little, there’s no reason it shouldn’t stay around these levels (with the PMDA around the corner, not knowing when it really gets announced and then it probably has a run) I’ve been following the company for years now, accumulating along the way so my average is lower than the current price, but I ain’t selling anytime soon I’m long and truly believe in the potential

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

Pristine_Hurry_4693

It’s a process, the treatment itself has proven to be effective 100% of the time (meaning there has yet to be a solid tumor that hasn’t responded, it’s basically physics). Now the “challenge” is to get access to the tumors in a safe way, to implement the treatment, which slowly (and ramping up quickly) has happened tumor type after tumor type. The company gets an approval to treat -> successfully treats (proving both safety and effectiveness) -> gets approval for larger scale trials -> success again -> and so on and so forth. They have 5 simultaneous IDE’s with one of them being phase 3 of the FDA, and that’s only in the US as they are treating in many other countries as well

Pristine_Hurry_4693

DRTS has many catalysts lined up: Yesterday successfully treated 1st GBM patient (IDE will continue and results will come) PMDA approval in Japan (near term, could be as soon as before EOY) Pancreas study progress and results (first patient was successfully treated) Phase 3 recruitment completion for cSCC New FDA trials launching (most recently prostate while next could be head & neck) Commercial manufacturing facility completion (recently approved by the FDA)

Pristine_Hurry_4693

They recently completed a 30-40 Pancreatic Cancer patients trial in Canada, they have 5 IDE’s going on with the cSCC being phase 3, and have 50+ clinical sites worldwide along with many years of preclinical treatments and data. The actual treatment is pretty much physics as you could see here: https://youtu.be/rLgMmDbJxJ8?si=3IiRl3pZ5v_OGHKW And there are patient testimonials there as well: https://youtu.be/3-wKoSCozA8?si=ZwTHE2JlrPTUadmY

Pristine_Hurry_4693

Great points! First note is that the treatment activates the immune system as well, since the treatment doesn’t harm the healthy tissue around the tumor it allows the body to learn to detect the cancer cells and how to attack them. To address the funnel, they could pretty much treat all shapes and sizes, but more importantly (to answer the business concerns) this treatment is effective for ALL solid tumors. Skin, head and neck, pancreas, lungs, breast, prostate and more have all been treated successfully in pre clinical and some already in clinical (they have five IDE’s live in the US), so the patient population (sadly) is millions of annually new cases. And lastly to the point about other countries, they already have clinical sites in the UK, Germany, Italy, France, Russia, Canada and more…

Pristine_Hurry_4693

First of all I’m 100% with you on the beat cancer front, that’s what’s really exciting about it (it just happens to be that if it is successful at saving millions of people it will then make investors millions of dollars). And on the FDA front, the FDA loves DRTS. They just granted them their FIFTH simultaneous IDE. They awarded them with Breakthrough Device Designation. Accepted them into the TAP program. Certified them with the MDSAP. And more…

Pristine_Hurry_4693

The ceiling is really high, the treatment is effective for all solid tumors, with dozens successfully tested in pre clinical trials (yet to find a tumor that doesn’t respond, including breast, lungs, pancreas, prostate, skin, head and neck etc) and 5(!) currently active IDE’s If we take just pancreas for example, and only in the US, that’s 60K new annual cases that would need the DRTS treatment, with a cost basis of say 100K$ that’s billions in annual revenue from one indication alone and only in the US. With a market cap of only ~350M… price target could be 10$+ easily (in the near term say a few months from now)

ImaginationBroad2590

They’re both early so it’s hard to directly compare without more data. I prefer the alpha radiation approach from DRTS, I think it will prove to be highly destructive to tumor cells without being impacted by the tumor’s micro environment and with no impact to surrounding healthy tissue. As an investor, taking the IDE pathway to approval versus the IND pathway is also a significant difference, although PSTV is well ahead in the development process for GBM…

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

Next_Discipline_2808

Here’s the news about the fifth IDE: https://www.alphatau.com/single-post/alpha-tau-receives-fda-approval-to-initiate-a-trial-for-patients-with-locally-recurrent-prostate-can

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

Pristine_Hurry_4693

Some seem to think that the GBM news could be a wake up call as well, and I could understand why. I don’t think the market is aware or understands that DRTS’s treatment could actually treat GBM, if that proves to be right (which it did in the earlier trials earning it the FDA Breakthrough Device Designation along with getting included in the FDA’s TAP program, and is now recruiting patients for the IDE) that could definitely get some attention as well.

Pristine_Hurry_4693

Spot on, there’s so much to love about it. Ppl treat the many IDE’s as if they are ‘many shots on goal’, although that might be true, and as none of them have been completed yet that might be of comfort for those afraid it might not get approved, but the truth of the matter is what you’ve said - it’s THE SAME treatment for all solid tumors, it’s just about proving they could reach and treat in a safe way. Each of the trials just further validates the treatment as it’s basic physics and works the same for all solid tumors, therefore increasing the TAM, which in DRTS’s case means more potential lives saved which is awesome to be a part of while enjoying the gains as well.

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

howtotailslide

They are paying cursor who does not have an AI model, it’s just an IDE that connects to existing models. Cursor is probably making money because they are not actually an AI company really, they are a customer. The existing AI models cost a shitload of energy and hardware to run, those companies are all hemorrhaging money like crazy lol

_hiddenscout

Not too much with the CLI tools. I work in test automation and do a lo more of the dev ops and what not for our pipelines on top of the test automation. Getting copilot into IDE has been great. Thing basically write code for you, but it only really works well if you have a foundation in code. Like to me, I think the days of being a JR developer is going to be way harder as companies just want to hire more experienced developers who work faster. I still think on the SaaS side of the world, you get more bottle necks from product. Like not getting good Acceptance Criteria on stories or bad designs. Being able to code faster is great, but doesn't mean you are going to ship faster, especially the larger the companies. The vibe coding stuff is cool. Kind of reminds me of like ruby on rails came out. Ruby on rails made it super easy to use a CLI and create everything you need for a web app. I just don't see a world, at least in bigger companies, where these tools are going to be more than productivity boosters. I do wonder if companies take a spin of building their own software first though.

EH_Story

The increase in screen understanding for Gemini 3 is such a massive game-changer for me and I don't believe the market has caught on yet. Antigravity is great as well, but screen-understanding has the potential to take agentic AI out of the IDE. This means potentially unlocking productivity benefits in back office functions outside of technology where the gains have so far been focused.

Clear_Anything1232

OpenAI is going to be ultra fucked by Googl The new model feedback is the exact opposite of how gpt 5 was received Apparently, they are crushing real world results and benchmarks Their new IDE has been tried by so many people that it crashed their login servers briefly I'm curious who will be dumb enough to throw money at openai in the next round

ectoblob

Yeah, Gemini 3 is also listed on Google's new IDE, 'Antigravity' page.

Pristine_Hurry_4693

I appreciate the genuine questions! Since it is a biotech stock, I believe the clinical trials failing, not getting FDA approval, running out of cash, and a general market crash are the biggest risks. I know I’m not necessarily supposed to counter, but for me a big part of the appeal of the stock is the risk management. The trials still might fail and there’s no way to know if and when the FDA will approve, but the results up to this day are amazing, and understanding how it works it’s basically physics that have been proven to work hundreds of time on dozens of tumors (every tumor tested has responded). The FDA has granted the treatment FDA breakthrough device designation, has accepted it into the FDA TAP program, it’s got MDSAP certification, FDA IDE’s for different cancer types, FDA approved its manufacturing facility and more so safe to say things are going well and the relationship with the FDA is a positive one. From the financial side they have runway for a few years, while the PMDA in Japan is expected to approve them to go to market very soon, and the FDA could as well for skin cancer (although their real goal is the inner organs) which could both mean it will no longer be pre-revenue.

ProudPeak3570

A fucking IDE is valued at 30B. This will collapse spectacularly

the__storm

Y Combinator just funded a startup building the "Chad IDE," which is an AI coding product that integrates brainrot activities directly into the interface while you wait for the LLM to generate your code. https://x.com/ycombinator/status/1988366241460089118 Too bad YC is private or I'd be all in, but at least we can dump some more money into NVDA.

JohanWuhan

Yes definitely. I’m using Juni in my IDE (Jetbrains IntelliJ). I think since Juni came out I can ship 5 times more features and it’s doing an amazing job. So let’s say, you have a backend which returns a list with users, and you want a react component to display those users. You can just tell Juni: “create a table component to display the users. Also add edit and delete buttons which should open modals”. That’s it. You can get some coffee and it will create it all for you. It analyses your codebase so all the code it’s generating will be in the same style. It’s like having multiple really good junior developers working for you. Is it perfect? No it’s not and you always have to check what it has done, but it saves me a lot of time.

Major_Complex5950

First of all The SI only 10%? And Its just getting approved for IDE (Investigational Device Exemption) and it will take atleast 2 years for the final PMA approval.

Major_Complex5950

The SI only 10%, And Its just getting approved for IDE (Investigational Device Exemption) and it will take atleast 2 years for the final PMA approval.

ireadfaces

PS: I am not bad mouthing the company. These are some of my observations, and I wanted honest opinions on what others know. So please take it as a discussion where I want to educate myself, rather than an attack on the company's future. I feel these numbers are barely moving. For a company that has been out for this long, at least that much growth is valid. Also, they are not pulling much (AWS revenue is 30+ billion) and Google cloud is at a third spot since inception. And their bread and butter, the search ads: You can yourself see that a lot of queries people used to make now go straight to ChatGPT (coding related queries to Claude or their GPT Powered IDE like Cursor). If these queries were still being funneled to gemini, it would have been a different ballgame, but given this data, I worry about the upcoming future unless they hit another killer product like Android.

ClideLennon

I remember the advent of Intellisense and how it mean not needing to look up method names in the docs anymore. That was a nice performance boost. I use Cursor with Claude 4 sonnet 4.5 as my daily IDE. I hit the tab key a bit more than when I was using copilot. It knows what I have in the clipboard and suggests that a lot. That's great. It's not doing any 5x or even 2x. It's just a nice tool. And it's all stuff I already knew how to do.

lax20attack

It really will! While it won't replace developers anytime soon, it's a great tool to use. It reminds me of the jump when IDE's started giving code auto complete suggestions. This is the next level to that.

MagicWishMonkey

I do dev work and I agree that agentic IDE's are the future, but it's not replacing anyone anytime soon. It's not a fun time to be on the job market, especially not if you're just starting your career. I use claude code on a daily basis and I'm in the process of rolling these tools out to my devs so I'm fairly familiar with them. I think what's happening right now is a confluence of factors where AI is just one dimension, it's a perfect storm of of economic uncertainty thanks to the idiots in the white house, uncertainty of how what the long term impact of AI will be, organizations cutting tech headcount because of the change to R&D accounting rules (which have recently been rolled back but it'll take time for orgs to adjust), and the glut of tech workers that have been flooding the market over the last decade or so because "everyone should learn how to code and make a million dollars".

lebroski_

No offense but IDE plug-ins used by code monkeys are only one use case. Some of us are software developers in the ai space making ai powered apps and it is taking us over a new threshold that wasnt possible even 2 years ago.

Playful-Voice-6250

1. Acoustic Science Division • Technologies like ADIO,WiSA,Sumerian , these are audio/wireless/acoustic-signal technologies • Use cases: triggering mobile devices via inaudible tones in ads, enabling audio-based consumer interactions, loyalty or rewards driven by audio cues.  2. Data Science & Data Monetization / Web 3.0 Platform • Products called DataScore, DataValue,Data Vault Bank — these are AI agents or engines that help enterprises assess the value / risk / quality of data, convert enterprise data into “structured, tradable assets,” price data, ensure regulatory compliance, etc.  • Information Data Exchange (IDE) / “Digital Twins” / licensing of name, image, likeness (NIL) / attaching metadata & immutable (blockchain) objects to real-world things.  3. Acquisitions & Licensing • Acquired CompuSystems, Inc. (CSI) assets (these are assets in event registration, data analytics, lead management for events, trade shows etc.). DVLT expects those to contribute to revenue and event-based customers.  • Licensing agreements, e.g. with NYIAX for ADIO (audio / advertising engagement), with GFT Rewards for using ADIO in mobile rewards/loyalty programs.  4. Partnerships • With IBM WatsoNx (watsonx.ai) to power DataScore, DataValue etc., to help with AI governance, compliance, infrastructure for data valuation.  • With CLEAR (for identity / KYC), to ensure identity verification in monetization / data exchange.  • Burke Products (defense / aerospace contracting partner) appears in their network. 

Pristine_Hurry_4693

Many are wary of Biotech, but just as all stocks it just needs the right research and situation. In short, DRTS is a life saving treatment, the company has the financial runway to execute, already has FDA breakthrough device designation and many more clinical and regulatory needs cleared, they are already treating patients in the US as part of the FDA IDE they have for multiple tumor types, the only thing lacking is awareness making it a under the radar play - with major catalysts coming as soon as this year (PMDA approval in Japan, GBM patient, Commercialization efforts, Strategic partnership deals…)

Temporary-Alarm-744

I mean how many fathers don’t get snipe by the IDE is it really the father part or being 31 that matters?

Pristine_Hurry_4693

I’ve already answered a different comment, so not to repeat I’ll try to add value and just say the stock already has: - FDA breakthrough device designation - FDA TAP program inclusion - FDA MDSAP certification - FDA IDE’s for several cancers - FDA trials (multiple) at phase 2 and 3 - Financial runway beyond commercialization - 2 manufacturing factories built and a 3rd and largest being built in the US - 100% tumor response rate in early FDA trials - Could treat high unmet needs cancers like Pancreatic, Lungs, Brain, Breast, etc… - Activates immune system response - 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, etc…) - Patents, IP and more… Some upcoming catalysts: They treated a Pancreatic Cancer patient initiating their IMPACT study, are approved to do the same for GBM, and are expecting PMDA approval in Japan this calendar year. Still one of the most under the radar and therefore undervalued plays in a multi hundred billion dollar life saving market.

Pristine_Hurry_4693

My pleasure, you should know they already have: - FDA breakthrough device designation - FDA TAP program inclusion - FDA MDSAP certification - FDA IDE’s for several cancers - FDA trials (multiple) at phase 2 and 3 - Financial runway beyond commercialization - 2 manufacturing factories built and a 3rd and largest being built in the US - 100% tumor response rate in early FDA trials - Could treat high unmet needs cancers like Pancreatic, Lungs, Brain, Breast, etc… - Activates immune system response - 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, etc…) - Patents, IP and more… Along with the expected PMDA approval and other clinical results Best of luck!

Pristine_Hurry_4693

My favorite pick is DRTS. The stock already has: - FDA breakthrough device designation - FDA TAP program inclusion - FDA MDSAP certification - FDA IDE’s for several cancers - FDA trials (multiple) at phase 2 and 3 - Financial runway beyond commercialization - 2 manufacturing factories built and a 3rd and largest being built in the US - 100% tumor response rate in early FDA trials - Could treat high unmet needs cancers like Pancreatic, Lungs, Brain, Breast, etc… - Activates immune system response - 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, etc…) - Patents, IP and more… This week they successfully initiated the IMPACT study by treating the first Pancreatic Cancer patient in the US, after successfully completing their trials with over 40 Pancreatic Cancer patients in Canada. Furthermore they are expecting PMDA approval in Japan this calendar year. One of the most undervalued plays in a multi hundred billion dollar life saving market.

greenpride32

The AI infused IDE's are all just forks from VS Code and using some other company's frontier models. More or less they've created what boils down to an AI plug-in masqueraded to look like they built a full product. VS Code already does the same with Copilot. How much business worth can this product have which has little if any IP? So capital markets will prop this up to the tune of billions maybe tens of billions. Some unsuspsecting investor says look an "AI" play, I better buy it in case it blows up like everything else "AI". The fact that GOOGL poached the talent from Winsurf just shows where the value is, in the employees and talent who can build a full stack proprietary soution that has value. If the "tool" Winsurf has is so valuable, wouldn't have GOOGL tried to just purchase it all?

derprondo

Bro you don’t even copy and paste anymore, the Cursor IDE is fully integrated to do everything right in the IDE. And I am like Rain Man now btw.

DevOpsMakesMeDrink

I’m aware of all this. I have said before it is like a dangerous junior. But you can keep it on task and have it summarize documentation on things you are working on locally right in your IDE. You can ask it to look at configurations of things like live resources in a kubernetes clusters or have it recommend best practices and look for things not following them. The result is, in the right context and situation, the engineer is not wasting time doing things that are not pushing forward things. Less time researching and learning. Sometimes they are even able to recognize misconfigured services when troubleshooting. So right now, it’s very useful in a very limited context. In however many years with everyone doing these actions I expect it will become better and better. There isn’t a way I can see to fix the lack of context AI has. But I think it will get better at not hallucinating and being able to generate and even manage (look up operators) infrastructure / services at acceptable quality. And on the way it will get better and better at doing the small things so engineers can focus on the thing they are building.

MudHot8257

>Protest. I have. >Disrupt the system. In what sense, join ICE and drag my feet? >Call your local politician and ask questions about what is happening. My local politicians in California are just as neutered as the rest of us constituents. You wouldn’t know that since you’re speaking from the sidelines, you jackass. >Rauwe questions about your political system where money can buy politicians. No idea what you meant by this but presumably you’re saying be a vocal advocate against political lobbyism. I’ve had dozens of talks about citizens united and the dangers of allowing super PACs to curry political favor in exchange for money. >Don’t buy from people like Bezos and Musk. Do you understand how deeply entwined these multi multi billionaires are in our economy? It’s not as simple as: “Cancel your prime subscription and Bezos will go broke”. Here’s an AI slop list of a whole slew of companies that are Amazon subsidiaries. Bookpages Telebook IMDb Junglee PlanetAll LiveBid.com Accept.com Alexa Internet e‑Niche Incorporated Convergence Corporation Tool Crib of the North Back to Basics Toys Leep Technology Inc. MindCorps Incorporated Egghead Software OurHouse.com Joyo.com BookSurge (now CreateSpace) Mobipocket CustomFlix smallparts.com Shopbop TextPayMe Digital Photography Review (DPReview) Brilliance Audio Withoutabox Audible Fabric.com AbeBooks Shelfari Reflexive Entertainment Box Office Mojo Lexcycle SnapTell Zappos Touchco Woot Amie Street (Songza) BuyVIP Quidsi (Diapers.com & Soap.com) Toby Press LoveFilm The Book Depository Pushbutton Yap (speech recognition) Double Helix Games Teachstreet Kiva Systems (now Amazon Robotics) Evi Avalon Books UpNext IVONA Software Liquavista TenMarks Education, Inc. ComiXology Amiato Twitch Interactive Rooftop Media GoodGame Annapurna Labs 2lemetry Shoefitr ClusterK AppThwack Elemental Technologies Safaba Translation Systems Biba Systems Orbeus Colis Privé NICE Emvantage Payments Cloud9 IDE Curse, Inc. Westland Partpic harvest.ai Thinkbox Software Do.com Whole Foods Market Souq.com Graphiq GameSparks Wing.ae Body Labs Goo Technologies (Sumerian) Dispatch (Amazon Scout) Blink Home Sqrrl Ring PillPack Tapzo CloudEndure TSO Logic Eero Canvas Technology Sizmek Ad Server & Dynamic Creative Optimization Bebo E8 Storage IGDB INLT Zoox Wondery Umbra 3D Metro‑Goldwyn‑Mayer (MGM Holdings) Art19 Wickr Veeqo Spirit.ai Fig MX Player One Medical Additional Amazon-Owned Brands, Divisions & Services A9.com Shopbop Prime Prime Now Amazon Appstore Amazon Cash Amazon Digital Software & Video Games Amazon Marketplace Amazon Pay Kindle Store 1‑Click Amazon Fresh Amazon Go Treasure Truck Alexa Amazon Fire Fire TV Kindle Amazon Halo Amazon Luna Astro Kuiper Systems (Project Kuiper) Whole Foods Market (duplicate of 79) PillPack (duplicate of 90) Amazon Home Services Neighbors App Amazon Web Services (AWS) Mechanical Turk AWS Services (Aurora, Glacier, SageMaker, Lambda, S3, EC2, etc.) Amazon Drive Body Labs (duplicate of 84) Maybe by some miracle you haven’t used a single one of these companies’ products, go ahead and look up your top 10 favorite websites and see how many are hosted through AWS. Why don’t you come over here and fight on the front lines with the people you’re disparaging, rather than kicking people that are currently experiencing it? If you lived here you’d be doing the same exact thing, if not even less advocacy. It’s easy to critique when you’re watching from the sidelines, it’s harder when you have to actually face consequences for your actions.

BicyclePurple

RDGL! Keep it on your radar. Awaiting IDE approval by August 15th.

Key-Spray4403

Fda IDE approval expedited mid aug

fredditf

Amazon Q2 ’25 Earnings Highlights 🔹 Sales: $167.7 B (Est. $162.15 B) 🟢; +13% YoY 🔹 EPS: $1.68 (Est. $1.33) 🟢 🔹 Oper Income: $19.2 B (Est. $16.77 B) 🟢 🔹 AWS Net Sales: $30.87 B (Est. $30.77 B) 🟢; +17.5% YoY Q3 Guidance 🔹 Net Sales $174.0 B–$179.5 B (Est. $173.24B) 🟢 🔹 Operating Income $15.5 B–$20.5 B Segment Performance North America 🔹 Sales: $100.1 B; UP +11% YoY 🔹 Operating Income: $7.5 B International 🔹 Sales: $36.8 B; UP +16% YoY 🔹 Operating Income: $1.5 B AWS 🔹 Operating Income: $10.2 B Other Metrics 🔹 Operating Cash Flow (TTM): $121.1 B; UP +12% YoY 🔹 Free Cash Flow (TTM): $18.2 B CEO Andy Jassy Commentary 🔸 “Our conviction that AI will change every customer experience is starting to play out as we’ve expanded Alexa+ to millions of customers, continue to see our shopping agent used by many millions of customers, launched AI models like DeepFleet that optimize productivity paths for our 1M+ robots, made it much easier for software developers to write code with Kiro (our new agentic IDE), launched Strands to make it easier to build AI agents, and released Bedrock AgentCore to enable agents to be operated securely and scalably.” 🔸 “Our AI progress across the board continues to improve our customer experiences, speed of innovation, operational efficiency, and business growth, and I’m excited for what lies ahead.”

MAGS0330

Hold for a while… should get a nice pop after 8/14 when the IDE IS accepted… will also rise nicely when progress from US clinical trials are posted

danfay222

As someone who works at Meta, I promise you they are not in “panic mode” on AI. The internal AI assistants and coding models are genuinely crazy, I don’t think a public version of any of them has been released (and I’m not sure it will be) but we genuinely have tools built into our IDE where I can just describe what I want and maybe link a design doc and it will do 90% of the work for me. There’s so many products currently in the works that don’t have industry equivalents, they’re not struggling their just piling on investments

MAGS0330

RDGL… cancer killing therapy, injectable gel that hardens in the tumor, destroying it from the inside out while leaving surrounding tissue undamaged. They just submitted their IDE to the FDA on 7/14, expect approval by 8/14… clinical trials to be done in the US with the most reputable cancer research institute in the world (Mayo Clinic). YOLO everything and become RICH!!!!

BicyclePurple

Hi! I just want to remind people to keep $RDGL on your radar. We will find out if they get IDE approval in August.

MAGS0330

Smart man. The IDE decision should be made by 8/15/25. I can’t imagine they would have submitted it without a very high degree of confidence that it will be approved. The pop should come after approval but i also think there are much higher long term gains in store once they start conducting the U.S. trials and positive data comes out

Pristine_Hurry_4693

Who - a company with a revolutionary cancer treatment Why - they could potentially save millions of lives and by doing so make you millions of dollars How - they have 100% tumor response rate in early FDA trials, their treatment is effective against all solid tumors including high unmet needs like pancreatic cancer, lung cancer, GBM, breast cancer and many more (dozens were tested and all responded, currently active in 50+ clinical sites worldwide including the US, Canada, France, Italy, Germany, UK, Russia and more). They have the financial runway to get to commercialization. They have manufacturing facilities. They have FDA breakthrough device designation. They have FDA TAP program inclusion. They have FDA MDSAP certification. They have FDA IDE’s and have multiple trials going on including phase 2 and 3 already. The treatment is a one time under an hour procedure, is lethal to the cancer cells while sparing healthy tissue and little to no side effects.

MAGS0330

Honestly, with the size of the Oncology market today, and the population of patient candidates that are not ideal for surgery, I think RDGL is well positioned to capture a large underserved market. There have been many numbers thrown around, but if they get their IDE and publish successful data from US Clinical trials I think it’s not crazy for this stock to breach $3.00 easy

throwawayainteasy

My work rolled out Copilot Chat. It can't tell if it's helpful or not because it crashes every time I start using it for anything intensive. Also annoying that it has some kind of hidden formatting/characters so anytime I try to use to to help with any kind of coding/scripting, I can't just copy and paste it's output into my IDE. Anything that's indented throws and error. I have re-do all the indents. Combined, that means even though it's more of a PITA to use from our computer systems and I have to be paranoid about not exposing propriety stuff, I still use the "more limited" free version of ChatGPT instead.

WhatWeMissed

The name was reused. If you thought cursor.ai was worth anything, AWS just added at least that much value with this release. Agentic AI in an IDE that interfaces smoothly with all AWS stack is pure gold.

MAGS0330

I’d grab as much as you can. High likelihood that this IDE will be successful. We should know by AUG 15. If it is, the company becomes a big buy out target, and even if they don’t want to sell— interest from institutional investors should be a big driver to aid in handsome returns